Results of Operations and Financial Condition. On November 5, 2026, NeOnc Technologies Holdings, Inc. (the “Company”) issued a press release reporting financial results for the third quarter ended September 30, 2026, and highlighted recent corporate and clinical progress. A copy of the press release is attached hereto as Exhibit 99.1 and the information therein is incorporated herein by reference. The information contained in this

Director — Steven L. Giannotta, M.D.: The filing reports the resignation of a director and the immediate appointment of a successor, which is a standard board composition change rather than the loss of a senior executive officer.

Material Modification to Rights of Security Holders. As previously reported on a Current Report on Form 8-K filed by NeOnc Technologies Holdings, Inc. (the “Company”) on September 10, 2026, the Company indicated that it would use the net proceeds from the sale of the Company’s shares of common stock from the registered direct offering to redeem the Company’s existing Series A Convertible Preferred Stock (“Series A Preferred Stock”). On September 15, 2026, the Company redeemed all outstanding…

Entry into a Material Definitive Agreement. Securities Purchase Agreement On September 8, 2026, NeOnc Technologies Holdings, Inc. (the “Company”) entered into securities purchase agreements (the “Purchase Agreement”) with certain institutional investors (the “Purchasers”) relating to the registered direct offering and sale of an aggregate of 2,610,715 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), pre-funded warrants (the “Pre-Funded War…

Director — Nasim Shomali: The filing discloses the appointment of a director to the Audit Committee, which is a routine board governance action rather than an executive departure.

Results of Operations and Financial Condition. On August 10, 2026, NeOnc Technologies Holdings, Inc. (the “Company”) issued a press release reporting second quarter financial results and confirmed that topline results from its fully enrolled Phase 2a NEO100 study will be presented on August 12, 2026. A copy of the press release is attached hereto as Exhibit 99.1 and the information therein is incorporated herein by reference. The information contained in this

Director — Ming-Fu (Alan) Chiang, M.D., Ph.D., MBA: Dr. Chiang resigned from the Board of Directors and Scientific Advisory Board.

On June 10, 2026, the Company amended its Certificate of Incorporation by filing the Certificate of Designations, Preferences and Rights of the Series A Preferred Stock (the “Certificate of Designation”) with the Secretary of State of the State of Delaware, which authorized the Series A Preferred Stock with such preferences and rights as set forth in the Certificate of Designation. General . The Company’s board of directors has designated six thousand (6,000) shares as the Series A Preferred…

Entry into a M aterial Definitive Agreement. On June 10, 2026, NeOnc Technologies Holdings, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain accredited investors (the “Investors”), pursuant to which the Company agreed to issue and sell up to an aggregate of $5,000,000 of its Series A Convertible Preferred Stock (the “Series A Preferred Stock”) in a private placement. The Series A Preferred Stock will be issued at a purchase price of $83…

The issuances of the shares of Series A Preferred Stock were not registered under the Securities Act of 1933, as amended (the “Securities Act”), but qualified for an exemption under Section 4(a)(2) of the Securities Act and by Rule 506 of Regulation D promulgated thereunder as transactions by an issuer not involving a public offering.

and in the accompanying Exhibit 99.1 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended (the “Securities Act”), except as shall be expressly set forth by specific reference in such filing.

Entry Into a Material Definitive Agreement As previously disclosed, on January 29, 2026, NeOnc Technologies Holdings, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Agreement”) to issue and sell up to 2,222,222 shares (the “Shares”) of common stock, $0.0001 par value per share of the Company (the “Common Stock”) at a per Share purchase price of $7.20 and five-year warrants to purchase up to 2,222,222 shares of Common Stock at a per share exercise price of $9.00 (the “…

Unregistered Sales of Equity Securities. The information contained in

Entry into a Material Definitive Agreement. At The Market Offering On April 10, 2026, the Company entered into an Equity Distribution Agreement (the “Agreement”) with BTIG, LLC and A.G.P./Alliance Global Partners (collectively, the “Placement Agents”) to create an “at the market” equity program under which it may sell up to an aggregate of $75,000,000 of shares of the Company’s common stock, par value $0.0001 per share (the “Shares”), from time to time through or to the Placement Agents, subj…

Results of Operations and Financial Condition. On April 1, 2026, NeOnc Technologies Holdings, Inc. (the “Company”) issued a press release reporting financial results for the fourth quarter and year ended December 31, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and the information therein is incorporated herein by reference. The information contained in this

Unregistered Sales of Equity Securities. The information contained in

Entry Into a Material Definitive Agreement As previously disclosed, on January 29, 2026, NeOnc Technologies Holdings, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Agreement”) to issue and sell up to 2,222,222 shares (the “Shares”) of common stock, $0.0001 par value per share of the Company (the “Common Stock”) at a per Share purchase price of $7.20 and five-year warrants to purchase up to 2,222,222 shares of Common Stock at a per share exercise price of $9.00 (the “…

Chief Accounting Officer — David Choi: David Choi was promoted to Chief Accounting Officer.

Entry into a Material Definitive Agreement. On March 12, 2026, NeOnc Technologies Holdings, Inc. (the “Company”) entered into an employment agreement (the “Employment Agreement”) with David Choi for his service as Chief Accounting Officer of the Company. The terms of Mr. Choi’s Employment Agreement provide for a base salary of $162,500 per year. In addition, Mr. Choi will be entitled to participate in the Company’s 2023 Equity Incentive Plan, with 170,000 restricted shares (the “Restricted Sh…

Entry Into a Material Definitive Agreement As previously disclosed, on January 29, 2026 NeOnc Technologies Holdings, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Agreement”) to issue and sell up to 2,222,222 shares (the “Shares”) of common stock, $0.0001 par value per share of the Company (the “Common Stock”) at a per Share purchase price of $7.20 and five-year warrants to purchase up to 2,222,222 shares of Common Stock at a per share exercise price of $9.00 (the “W…

Unregistered Sales of Equity Securities. The information contained in

Unregistered Sales of Equity Securities. The information contained in

Entry Into a Material Definitive Agreement On January 29, 2026, NeOnc Technologies Holdings, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Agreement”) to issue and sell up to 2,222,222 shares (the “Shares”) of common stock, $0.0001 par value per share of the Company (the “Common Stock”) at a per Share purchase price of $7.20 and five-year warrants to purchase up to 2,222,222 shares of Common Stock at a per share exercise price of $9.00 (the “Warrants” and together wi…

Entry Into a Material Definitive Agreement On December 1, 2025, NeOnc Technologies Holdings, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Agreement”) with Saad Naja (the “Investor”) to issue and sell 111,732 shares (the “Shares”) of common stock, $0.0001 par value per share of the Company (the “Common Stock”). The per share purchase price of the Shares is $8.95, which represents the closing price of the Common Stock as reported on the Nasdaq Capital Market on Novemb…

Unregistered Sales of Equity Securities. The information contained in